StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of NASDAQ:GLMD remained flat at $0.39 during trading on Thursday. 22,429 shares of the company’s stock traded hands, compared to its average volume of 261,749. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The firm’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.38.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Find and Profitably Trade Stocks at 52-Week Lows
- MarketBeat Week in Review – 4/29 – 5/3
- How to Invest in Blue Chip Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Investing in the High PE Growth Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
